Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Said R Beydoun

Showing results (21-30 of 36) with videos related to

Pageof 4
Sort By:
Journal of Clinical Neuromuscular Disease|April 28, 2012
Clinical and imaging findings in three patients with advanced inflammatory demyelinating polyradiculoneuropathy associated with nerve root hypertrophySaid R Beydoun, Jason Muir, Rami G Apelian, et al.
Frontiers in Neurology|December 17, 2020
Concomitant Immunosuppressive Therapy Use in Eculizumab-Treated Adults With Generalized Myasthenia Gravis During the REGAIN Open-Label Extension StudyRichard J Nowak, Srikanth Muppidi, Said R Beydoun, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|January 17, 2026
A novel case of compound heterozygous GFPT1 congenital myasthenic syndrome with a coexisting heterozygous DYSF mutation: clinical and pathological insightsKamran Moradi, Leila Darki, Ryan W Rebbe, et al.
Frontiers in Neurology|March 25, 2021
Individualizing Therapy in CIDP: A Mini-Review Comparing the Pharmacokinetics of Ig With SCIg and IVIgSaid R Beydoun, Khema R Sharma, Bassam A Bassam, et al.
Clinical Neurology and Neurosurgery|July 17, 2021
Reducing body myopathy associated with the LIM2 p.(His123Arg) FHL1 variantLeila Darki, Arash Jalali-Sohi, Samuel Guzman, et al.
Journal of the Peripheral Nervous System : JPNS|April 15, 2014
A controlled trial of intravenous immunoglobulin in multifocal motor neuropathyAngelika F Hahn, Said R Beydoun, Victoria Lawson, et al.
Pain and Therapy|August 13, 2022
Clinical Meaningfulness of Response to Tanezumab in Patients with Chronic Low Back Pain: Analysis From a 56-Week, Randomized, Placebo- and Tramadol-Controlled, Phase 3 TrialJohn D Markman, Thomas J Schnitzer, Serge Perrot, et al.
European Journal of Neurology|May 20, 2026
Evaluation of Sustained Disease Control With Nipocalimab Versus Placebo in the Phase 3 Vivacity-MG3 StudyTuan Vu, Said R Beydoun, Richard J Nowak, et al.
Frontiers in Neurology|February 6, 2024
Long-term safety, tolerability, and efficacy of efgartigimod (ADAPT+): interim results from a phase 3 open-label extension study in participants with generalized myasthenia gravisJames F Howard, Vera Bril, Tuan Vu, et al.
Neurology|July 3, 2020
Minimal manifestation status and prednisone withdrawal in the MGTX trialIkjae Lee, Hui-Chien Kuo, Inmaculada B Aban, et al.
Pageof 4

Showing results (21-30 of 36) with videos related to

Sort By:
Pageof 4
Journal of Clinical Neuromuscular Disease|April 28, 2012
Clinical and imaging findings in three patients with advanced inflammatory demyelinating polyradiculoneuropathy associated with nerve root hypertrophySaid R Beydoun, Jason Muir, Rami G Apelian, et al.
Frontiers in Neurology|December 17, 2020
Concomitant Immunosuppressive Therapy Use in Eculizumab-Treated Adults With Generalized Myasthenia Gravis During the REGAIN Open-Label Extension StudyRichard J Nowak, Srikanth Muppidi, Said R Beydoun, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|January 17, 2026
A novel case of compound heterozygous GFPT1 congenital myasthenic syndrome with a coexisting heterozygous DYSF mutation: clinical and pathological insightsKamran Moradi, Leila Darki, Ryan W Rebbe, et al.
Frontiers in Neurology|March 25, 2021
Individualizing Therapy in CIDP: A Mini-Review Comparing the Pharmacokinetics of Ig With SCIg and IVIgSaid R Beydoun, Khema R Sharma, Bassam A Bassam, et al.
Clinical Neurology and Neurosurgery|July 17, 2021
Reducing body myopathy associated with the LIM2 p.(His123Arg) FHL1 variantLeila Darki, Arash Jalali-Sohi, Samuel Guzman, et al.
Journal of the Peripheral Nervous System : JPNS|April 15, 2014
A controlled trial of intravenous immunoglobulin in multifocal motor neuropathyAngelika F Hahn, Said R Beydoun, Victoria Lawson, et al.
Pain and Therapy|August 13, 2022
Clinical Meaningfulness of Response to Tanezumab in Patients with Chronic Low Back Pain: Analysis From a 56-Week, Randomized, Placebo- and Tramadol-Controlled, Phase 3 TrialJohn D Markman, Thomas J Schnitzer, Serge Perrot, et al.
European Journal of Neurology|May 20, 2026
Evaluation of Sustained Disease Control With Nipocalimab Versus Placebo in the Phase 3 Vivacity-MG3 StudyTuan Vu, Said R Beydoun, Richard J Nowak, et al.
Frontiers in Neurology|February 6, 2024
Long-term safety, tolerability, and efficacy of efgartigimod (ADAPT+): interim results from a phase 3 open-label extension study in participants with generalized myasthenia gravisJames F Howard, Vera Bril, Tuan Vu, et al.
Neurology|July 3, 2020
Minimal manifestation status and prednisone withdrawal in the MGTX trialIkjae Lee, Hui-Chien Kuo, Inmaculada B Aban, et al.
Pageof 4